163 related articles for article (PubMed ID: 21178146)
21. High mobility group box protein-1 in experimental autoimmune uveoretinitis.
Watanabe T; Keino H; Sato Y; Kudo A; Kawakami H; Okada AA
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2283-90. PubMed ID: 19151394
[TBL] [Abstract][Full Text] [Related]
22. [Retinal tissue damage and lipid peroxidation in experimental autoimmune uveoretinitis].
Goto H
Nippon Ganka Gakkai Zasshi; 1991 May; 95(5):455-61. PubMed ID: 1872217
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal injection of Tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in Rats.
Oh-i K; Keino H; Goto H; Yamakawa N; Murase K; Usui Y; Kezuka T; Sakai J; Takeuchi M; Usui M
Br J Ophthalmol; 2007 Feb; 91(2):237-42. PubMed ID: 16987901
[TBL] [Abstract][Full Text] [Related]
24. Kinetics of apoptotic cells in experimental autoimmune uveoretinitis.
Sueda J; Hikita N; Mochizuki M; Jimi A; Kojiro M
Invest Ophthalmol Vis Sci; 2000 Mar; 41(3):799-804. PubMed ID: 10711696
[TBL] [Abstract][Full Text] [Related]
25. Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats.
Okada AA; Sakai J; Usui M; Mizuguchi J
Ocul Immunol Inflamm; 1998 Jun; 6(2):111-20. PubMed ID: 9689641
[TBL] [Abstract][Full Text] [Related]
26. Fas expression and apoptosis in rats with experimental autoimmune uveoretinitis.
Abe T; Nakajima A; Satoh N; Sakuragi S
Jpn J Ophthalmol; 2001; 45(3):240-6. PubMed ID: 11369372
[TBL] [Abstract][Full Text] [Related]
27. Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats.
Kurose S; Ikeda E; Tokiwa M; Hikita N; Mochizuki M
Exp Eye Res; 2000 Jan; 70(1):7-15. PubMed ID: 10644416
[TBL] [Abstract][Full Text] [Related]
28. Preparation and characterization of a nanoparticulate formulation composed of PEG-PLA and PLA as anti-inflammatory agents.
Ishihara T; Takahashi M; Higaki M; Mizushima Y; Mizushima T
Int J Pharm; 2010 Jan; 385(1-2):170-5. PubMed ID: 19837147
[TBL] [Abstract][Full Text] [Related]
29. Effects of cyclosporine and other immunosuppressive drugs on experimental autoimmune uveoretinitis in rats.
Mochizuki M; Nussenblatt RB; Kuwabara T; Gery I
Invest Ophthalmol Vis Sci; 1985 Feb; 26(2):226-32. PubMed ID: 3871750
[TBL] [Abstract][Full Text] [Related]
30. Effects of a new dexamethasone-delivery system (Surodex) on experimental intraocular inflammation models.
Kodama M; Numaga J; Yoshida A; Kaburaki T; Oshika T; Fujino Y; Wu GS; Rao NA; Kawashima H
Graefes Arch Clin Exp Ophthalmol; 2003 Nov; 241(11):927-33. PubMed ID: 14652765
[TBL] [Abstract][Full Text] [Related]
31. Microarray analysis of cytokine and chemokine gene expression after prednisolone treatment in murine experimental autoimmune uveoretinitis.
Hashida N; Ohguro N; Nakai K; Kobashi-Hashida M; Hashimoto S; Matsushima K; Tano Y
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4224-34. PubMed ID: 16249502
[TBL] [Abstract][Full Text] [Related]
32. IL-18 not required for IRBP peptide-induced EAU: studies in gene-deficient mice.
Jiang HR; Wei X; Niedbala W; Lumsden L; Liew FY; Forrester JV
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):177-82. PubMed ID: 11133864
[TBL] [Abstract][Full Text] [Related]
33. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide.
Keino H; Kezuka T; Takeuchi M; Yamakawa N; Hattori T; Usui M
Arch Ophthalmol; 2004 Aug; 122(8):1179-84. PubMed ID: 15302659
[TBL] [Abstract][Full Text] [Related]
34. Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis.
Luo L; Yang J; Oh Y; Hartsock MJ; Xia S; Kim YC; Ding Z; Meng T; Eberhart CG; Ensign LM; Thorne JE; Stark WJ; Duh EJ; Xu Q; Hanes J
J Control Release; 2019 Feb; 296():68-80. PubMed ID: 30660629
[TBL] [Abstract][Full Text] [Related]
35. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown.
Luna JD; Chan CC; Derevjanik NL; Mahlow J; Chiu C; Peng B; Tobe T; Campochiaro PA; Vinores SA
J Neurosci Res; 1997 Aug; 49(3):268-80. PubMed ID: 9260738
[TBL] [Abstract][Full Text] [Related]
36. Experimental autoimmune uveoretinitis (EAU)-related tissue damage and angiogenesis is reduced in CCL2⁻/⁻CX₃CR1gfp/gfp mice.
Zhao J; Chen M; Xu H
Invest Ophthalmol Vis Sci; 2014 Oct; 55(11):7572-82. PubMed ID: 25342612
[TBL] [Abstract][Full Text] [Related]
37. Modulating phenotype and cytokine production of leucocytic retinal infiltrate in experimental autoimmune uveoretinitis following intranasal tolerance induction with retinal antigens.
Laliotou B; Dick AD
Br J Ophthalmol; 1999 Apr; 83(4):478-85. PubMed ID: 10434874
[TBL] [Abstract][Full Text] [Related]
38. [Superoxide generated by polymorphonuclear leukocytes and retinal lipid peroxidation in uveoretinitis].
Goto H; Yamakawa N; Hasemi M; Matsuura G; Usui M
Nippon Ganka Gakkai Zasshi; 1994 Oct; 98(10):1019-26. PubMed ID: 7976823
[TBL] [Abstract][Full Text] [Related]
39. Apoptosis of infiltrating cells in experimental autoimmune uveoretinitis.
Yang P; Herzberg NH; Zhou H; Broersma L; de Smet M; Kijlstra A
Chin Med J (Engl); 2000 Jul; 113(7):643-6. PubMed ID: 11776038
[TBL] [Abstract][Full Text] [Related]
40. High-efficacy site-directed drug delivery system using sialyl-Lewis X conjugated liposome.
Hashida N; Ohguro N; Yamazaki N; Arakawa Y; Oiki E; Mashimo H; Kurokawa N; Tano Y
Exp Eye Res; 2008 Jan; 86(1):138-49. PubMed ID: 18036523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
